AASLD/IDSA HCV guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;(62):932-954.
Abdel-Alem S, ElSharkawy AM, Fouad R, et al. Improvement of glycemic state among responders to sofosbuvir-based treatment regimens: single center experience. J Med Virol. 2017;89:2181-2187.
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Infectious Disease Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):e1-34.
Abergel A, Hezode C, Asselah T, et al. A phase 3, global, multicenter, open-label study to investigate the efficacy of elbasvir/grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis: STREAGER. The International Liver Congress. 2018.
Abergel A, Asselah T, Metivier S, Loustaud-Ratti V. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16(4):459-464.
Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64(4):1049-1056.
Substance Abuse and Mental Health Services Administration. Medication-assisted treatment, naltrexone. 2020;Updated September 15, 2020. Accessed June 8, 2021. Available at:
Information sheet on naltrexone therapy. 2019. Available at:
Afdhal NH, Bacon BR, Patel K, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015;13(4):772-779.
Afdhal NH, Zeuzem S, Kwo PY, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
Afdhal NH, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
Agarwal K, Castells L, Mullhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol. 2018;69(3):603-607. doi:10.1016/j.jhep.2018.05.039.
Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495.
Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial. Ann Intern Med. 2019;170(9):594-603.
Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C screening of the "birth cohort" (born 1945-1965) and younger inmates of New York City jails. Am J Public Health. 2016;106(7):1276-1277.
Akiyama MJ, Lipsey D, Heo M, et al. Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy. Clin Infect Dis. 2020;70(12):2695-2702.
Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138(3):187-190.
Allison RD, Tong X, Moorman AC, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. J Hepatol. 2015;63(4):822-828.
Alonso S, Riveiro-Barciela M, Fernández I, et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat. 2017;24(4):304 - 311.
Alter MJ, Kuhnert WL, Finelli L, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep. 2003;52(RR-3):1-13, 15.